Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.

[1]  Glenn A. Maston,et al.  A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders , 2015, Human mutation.

[2]  T. Ross,et al.  Use of panel tests in place of single gene tests in the cancer genetics clinic , 2015, Clinical genetics.

[3]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[4]  Gail P Jarvik,et al.  The FDA and genomic tests--getting regulation right. , 2015, The New England journal of medicine.

[5]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[6]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[7]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[8]  R. Lea,et al.  The p.Ala510Val mutation in the SPG7 (paraplegin) gene is the most common mutation causing adult onset neurogenetic disease in patients of British ancestry , 2013, Journal of Neurology.

[9]  L. H. van den Berg,et al.  Genotype-phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort. , 2012, Brain : a journal of neurology.

[10]  I. Kohane,et al.  Taxonomizing, sizing, and overcoming the incidentalome , 2012, Genetics in Medicine.

[11]  Shih-Jen Chen,et al.  Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A) , 2010, Journal of Inherited Metabolic Disease.

[12]  Y. Chien,et al.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later‐onset GLA mutation c.936+919G>A (IVS4+919G>A) , 2009, Human mutation.

[13]  Alexander F. Wilson,et al.  Research in Genomic Medicine the Clinseq Project: Piloting Large-scale Genome Sequencing for Material Supplemental , 2009 .

[14]  Douglas F Easton,et al.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model , 2008, Human mutation.

[15]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[16]  Klaus Krippendorff,et al.  Answering the Call for a Standard Reliability Measure for Coding Data , 2007 .

[17]  A. Durr,et al.  Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia , 2006, Neurology.

[18]  K. Krippendorff.  Reliability in Content Analysis: Some Common Misconceptions and Recommendations , 2004 .

[19]  R. Desnick,et al.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. , 2002, American journal of human genetics.

[20]  C. Stanley,et al.  Mutations in BTD causing biotinidase deficiency , 2001, Human mutation.

[21]  Sergio Cocozza,et al.  Spastic Paraplegia and OXPHOS Impairment Caused by Mutations in Paraplegin, a Nuclear-Encoded Mitochondrial Metalloprotease , 1998, Cell.

[22]  G. Buck,et al.  Mutation (Q456H) is the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States. , 1997, Biochemical and molecular medicine.

[23]  R. Zwick,et al.  Another look at interrater agreement. , 1988, Psychological bulletin.

[24]  Dale J. Prediger,et al.  Coefficient Kappa: Some Uses, Misuses, and Alternatives , 1981 .

[25]  Klaus Krippendorff,et al.  Content Analysis: An Introduction to Its Methodology , 1980 .